<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129996</url>
  </required_header>
  <id_info>
    <org_study_id>SCHBCC-N025</org_study_id>
    <nct_id>NCT04129996</nct_id>
  </id_info>
  <brief_title>A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)</brief_title>
  <official_title>Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer: An Open, Single-arm, Multicenter, Efficacy and Safety Phase II Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, safety of camrelizumab in combination&#xD;
      with nab-paclitaxel and famitinib in Patients with unresectable locally advanced or&#xD;
      metastatic immunomodulatory triple negative breast Cancer..&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Baseline up to 53 months (assessed at Screening, every 8 weeks for the first 12 months, thereafter every 12 weeks until disease progression or death, whichever occurs first</time_frame>
    <description>Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 in all Participants</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>camrelizumab in combination with nab-paclitaxel and famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camrelizumab in combination with nab-paclitaxel and famitinib</intervention_name>
    <description>camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer</description>
    <arm_group_label>camrelizumab in combination with nab-paclitaxel and famitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG Performance Status of 0-1&#xD;
&#xD;
          -  Expected lifetime of not less than three months&#xD;
&#xD;
          -  Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER,&#xD;
             and PR expression)&#xD;
&#xD;
          -  Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by&#xD;
             the researchers could not be radical resection.&#xD;
&#xD;
          -  Adequate hematologic and end-organ function, laboratory test results.&#xD;
&#xD;
          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1&#xD;
             (RECIST v1.1)&#xD;
&#xD;
          -  Patients had received no previous chemotherapy or targeted therapy for metastatic&#xD;
             triple-negative breast cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g.&#xD;
             famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients .&#xD;
&#xD;
          -  A history of bleeding, any serious bleeding events.&#xD;
&#xD;
          -  Important blood vessels around tumors has been infringed and high risk of bleeding.&#xD;
&#xD;
          -  Coagulant function abnormality&#xD;
&#xD;
          -  artery/venous thromboembolism event&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C&#xD;
&#xD;
          -  Uncontrolled pleural effusion and ascites&#xD;
&#xD;
          -  Known central nervous system (CNS) disease.&#xD;
&#xD;
          -  Long-term unhealing wound or incomplete healing of fracture&#xD;
&#xD;
          -  urine protein ≥2+ and 24h urine protein quantitative &gt; 1 g.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Thyroid dysfunction.&#xD;
&#xD;
          -  Peripheral neuropathy grade ≥2.&#xD;
&#xD;
          -  People with high blood pressure;&#xD;
&#xD;
          -  A history of unstable angina;&#xD;
&#xD;
          -  New diagnosis of angina pectoris.&#xD;
&#xD;
          -  Myocardial infarction incident ;&#xD;
&#xD;
          -  Arrhythmia for long-term use of anti-arrhythmic drugs and New York heart association&#xD;
             class II or higher cardiac insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhimin shao, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ZHONGHUA WANG, MD,PHD</last_name>
    <phone>+86 021-6417559</phone>
    <email>zhonghuawang95@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LI CHEN</last_name>
    <phone>+86 021-6417559</phone>
    <email>chen_li@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhi-Ming Shao</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Ming Shao</last_name>
      <email>zhimingshao@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

